Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Lyell Immunopharma (LYEL) over the last 7 years, with Q3 2025 value amounting to $123.6 million.

  • Lyell Immunopharma's Cash & Equivalents rose 2320.66% to $123.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.6 million, marking a year-over-year increase of 2320.66%. This contributed to the annual value of $105.6 million for FY2024, which is 2749.8% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Cash & Equivalents stood at $123.6 million, which was up 2320.66% from $98.8 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Cash & Equivalents ranged from a high of $564.4 million in Q2 2021 and a low of $98.8 million during Q2 2025
  • Its 5-year average for Cash & Equivalents is $196.7 million, with a median of $133.4 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 19174.59% in 2021, then crashed by 7044.22% in 2022.
  • Over the past 5 years, Lyell Immunopharma's Cash & Equivalents (Quarter) stood at $293.8 million in 2021, then plummeted by 57.95% to $123.6 million in 2022, then increased by 17.88% to $145.6 million in 2023, then fell by 27.5% to $105.6 million in 2024, then grew by 17.03% to $123.6 million in 2025.
  • Its Cash & Equivalents was $123.6 million in Q3 2025, compared to $98.8 million in Q2 2025 and $120.3 million in Q1 2025.